Skip to main content

Table 2 Analysis of the change in visual acuity and change in the central foveal thickness within a short 3-month follow-up after treatment with anti-VEGF and comparison among the three agents, namely ranibizumab (RBZ), bevacizumab (BEV) and biosimilar ranibizumab (BSR)

From: Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation

nAMD short follow-up RBZ (n = 40) BEV (n = 35) BSR (n = 40) RBZ vs BEV
p value
BEV vs BSR
p value
RBZ vs BSR
p value
BCVA       
 Pre-treatment 0.59 ± 0.59 0.45 ± 0.23 0.77 ± 0.65 0.99 0.10 0.15
 Post-treatment 0.42 ± 0.4 0.36 ± 0.26 0.51 ± 0.42 0.32 0.68 0.25
 p value 0.007 0.007 0.004    
 Change in BCVA (95% CI) 0.17 ± 0.37 (− 0.06 to 0.22) 0.09 ± 0.23 (− 0.01 to 0.35) 0.26 ± 0.48 (− 0.29 to 0.11) 0.99 0.60 0.62
CFT       
 Pre-treatment 302.15 ± 203.84 302.15 ± 203.84 297.34 ± 154.88 0.74 0.36 0.17
 Post-treatment 178.82 ± 98.55 212.68 ± 100 259.14 ± 240.22 0.01 0.96 0.10
 p value < 0.01 < 0.01 < 0.01    
 Change in CFT (95% CI) 123.33 ± 209.91 (− 45.73 to 123.09) 84.65 ± 152.38 (− 46.06 to 97.32) 110.28 ± 148.19 (− 70.51 to 96.61) 0.34 0.52 0.57
Macular edema short follow-up RBZ (n = 29) BEV (n = 31) BSR (n = 27) RBZ vs BEV
p value
BEV vs BSR
p value
RBZ vs BSR
p value
BCVA       
 Pre-treatment 0.62 ± 0.41 0.54 ± 0.30 0.63 ± 0.33 0.64 0.32 0.75
 Post-treatment 0.47 ± 0.30 0.37 ± 0.18 0.37 ± 0.29 0.17 0.72 0.21
 p value 0.007 0.001 < 0.01    
 Change in BCVA (95% CI) 0.15 ± 0.27 (− 0.13 to 0.11) 0.16 ± 0.22 (− 0.04 to 0.22) 0.25 ± 0.27 (− 0.24 to 0.04) 0.59 0.24 0.13
CFT       
 Pre-treatment 628.89 ± 247.38 574.48 ± 211.29 587.44 ± 231.07 0.36 0.69 0.63
 Post-treatment 441.82 ± 222.63 433.55 ± 177.33 305.74 ± 163.15 0.39 0.37 0.97
 p value 0.006 0.001 < 0.01    
 Change in CFT (95% CI) 187.07 ± 321.86 (− 94.27 to 186.55) 140.93 ± 194.25 (0.75–280.78) 281.70 ± 314.71 (− 266.79 to 77.53) 0.99 0.07 0.16
  1. Significant p values are in bold type